IRWD
Ironwood Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-31/100
Last price
3.61
▼ 0.04 (1.10%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
3.64
Prev close
3.65
Day high
3.68
Day low
3.60
Volume
1.87M
Market cap
$599.82M
P/E (TTM)
4.78
52W range
1.41 – 5.78
Day trading desk
Gap from prior close
-0.28%
Prior close 3.65
VWAP
3.64
-0.72% from price
Relative volume
0.74×
Normal
Session range
3.35%
3.56 – 3.68
Position in range
42%
Mid range
ATR (14D)
0.20
5.46% of price
Prior day high
3.67
PDH
Prior day low
3.55
PDL
Bid / ask spread
—
Quote not published
Session volume
1.55M
Avg 2.08M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-12.74%
-14.7%
1M
-14.79%
-15.9%
3M
-23.90%
-28.4%
6M
+4.91%
-13.3%
YTD
+7.72%
-6.5%
1Y
+134.19%
+117.8%
3Y
-62.31%
-144.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on IRWD open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+461.01K
Net buying
Buy transactions
9
610.47K shares
Sell transactions
2
149.46K shares
Net transactions
+11
Buys less sells
Sell : buy shares
0.2 : 1
Mixed
Insider-held shares
5.35M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 20, 26 | SILBER JEFFREY M.D. Officer |
STOCK | 137.04K | $0 | Direct |
| Jul 7, 26 | SILVER RONALD Officer |
SELL | 127.89K | $578.06K | Direct |
| Jun 16, 26 | SHEPARD JAY P. Director |
STOCK | 63.48K | $0 | Direct |
| Jun 16, 26 | DUANE JON R Director |
STOCK | 63.48K | $0 | Direct |
| Jun 16, 26 | DENNER ALEXANDER J Director |
STOCK | 67.55K | $0 | Direct |
| Jun 16, 26 | MOUKHEIBIR CATHERINE Director |
STOCK | 63.48K | $0 | Direct |
| Jun 16, 26 | MCHUGH JULIE H Director |
STOCK | 63.48K | $0 | Direct |
| Jun 16, 26 | CURRIE MARK G Director |
STOCK | 63.48K | $0 | Direct |
| Jun 16, 26 | KESSLER MARLA L Director |
STOCK | 63.48K | $0 | Direct |
| Jun 16, 26 | MCHUGH JULIE H Director |
SELL | 21.57K | $80.46K | Direct |
| May 19, 26 | SILVER RONALD Chief Financial Officer |
STOCK | 25.00K | $0 | Direct |
| Mar 17, 26 | DENNER ALEXANDER J Director |
SELL | 6.73M | $20.53M | Indirect |
| Mar 13, 26 | DENNER ALEXANDER J Director |
STOCK | 4.45K | $0 | Direct |
| Mar 10, 26 | SHETZLINE MICHAEL Officer |
STOCK | 136.61K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CURRIE MARK G |
Director | 676.90K | Stock Award(Grant) |
DAVIS ANDREW RYAN |
Officer | 284.69K | Sale |
DENNER ALEXANDER J |
Director | 323.86K | Stock Award(Grant) |
EMANY SRAVAN KUMAR |
Chief Operating Officer | 309.57K | Sale |
GASKINS TAMMI L |
Officer | 350.35K | Stock Award(Grant) |
MARTINI GREGORY S. |
Chief Financial Officer | 297.21K | Stock Award(Grant) |
MCCOURT THOMAS A |
Chief Executive Officer | 1.90M | Stock Award(Grant) |
MINARDO JOHN |
Officer | 500.50K | Stock Award(Grant) |
SHETZLINE MICHAEL |
Officer | 658.04K | Stock Award(Grant) |
SILVER RONALD |
Officer | 313.68K | Sale |
Fundamentals
Market cap$599.82M
Enterprise value$917.56M
Revenue (TTM)$389.32M
Gross profit$300.62M
EBITDA$238.10M
Net income$129.87M
EPS (TTM)$0.76
Free cash flow$121.83M
Total cash$79.13M
Total debt$396.87M
Book value / share$-0.98
Shares outstanding165.24M
Float136.76M
Short % of float12.38%
Dividend yield0.00%
Beta (5Y)0.22
Valuation & profitability ratios
Trailing P/E4.78
Forward P/E2.42
PEG ratio—
Price / sales—
Price / book—
EV / revenue2.36
EV / EBITDA3.85
Gross margin77.22%
Operating margin70.16%
Profit margin33.36%
Return on equity—
Return on assets47.02%
Debt / equity—
Current ratio6.06
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $296.15M | $351.41M | $442.74M | $410.60M | — | -15.7% |
| Operating revenue | $296.15M | $351.41M | $442.74M | $410.60M | — | -15.7% |
| Cost of revenue | — | — | — | $0 | $0 | — |
| Gross profit | — | — | — | $410.60M | $413.75M | — |
| Research & development | $95.14M | $111.42M | $116.08M | $44.27M | — | -14.6% |
| Selling, general & admin | $82.26M | $144.27M | $158.31M | $115.99M | — | -43.0% |
| Total operating expense | $177.39M | $255.69M | $274.40M | $160.26M | — | -30.6% |
| Operating income | $118.76M | $95.72M | $168.34M | $250.34M | — | +24.1% |
| Net interest income | -$28.67M | -$28.57M | -$2.66M | $1.90M | — | -0.4% |
| Pre-tax income | $70.03M | $65.20M | -$948.07M | $252.42M | — | +7.4% |
| Tax provision | $46.01M | $64.32M | $83.49M | $77.36M | — | -28.5% |
| Net income | $24.02M | $880.00K | -$1.00B | $175.06M | — | +2,629.2% |
| Net income to common | $24.02M | $880.00K | -$1.00B | $175.06M | — | +2,629.2% |
| Basic EPS | 0.15 | 0.01 | -6.45 | 1.13 | — | +1,400.0% |
| Diluted EPS | 0.15 | 0.01 | -6.45 | 0.96 | — | +1,400.0% |
| EBIT | $102.77M | $98.23M | -$926.44M | $260.02M | — | +4.6% |
| EBITDA | $104.65M | $100.24M | -$924.87M | $261.44M | — | +4.4% |
| Basic shares | 161.84M | 159.08M | 155.44M | 154.37M | — | +1.7% |
| Diluted shares | 162.98M | 160.08M | 155.44M | 186.31M | — | +1.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $215.46M | $88.56M | $92.15M | $656.20M | — | +143.3% |
| Cash & short-term investments | $215.46M | $88.56M | $92.15M | $656.20M | — | +143.3% |
| Accounts receivable | $46.74M | $81.89M | $129.12M | $115.46M | — | -42.9% |
| Total current assets | $274.18M | $182.37M | $233.29M | $780.63M | — | +50.3% |
| Property, plant & equipment | $12.75M | $15.52M | $18.17M | $20.31M | — | -17.9% |
| Goodwill & intangibles | $2.04M | $2.86M | $3.68M | $0 | — | -28.7% |
| Total assets | $396.90M | $350.91M | $471.07M | $1.10B | — | +13.1% |
| Total current liabilities | $242.22M | $38.85M | $276.10M | $25.52M | — | +523.5% |
| Current debt | $199.68M | — | $199.56M | — | $116.86M | — |
| Long-term debt | $385.00M | $583.99M | $498.31M | $396.25M | — | -34.1% |
| Total debt | $597.80M | $599.48M | $715.54M | $415.92M | — | -0.3% |
| Total liabilities | $658.74M | $652.24M | $817.37M | $448.14M | — | +1.0% |
| Retained earnings | -$1.67B | -$1.70B | -$1.70B | -$696.38M | — | +1.4% |
| Shareholder equity | -$261.83M | -$301.33M | -$346.30M | $652.38M | — | +13.1% |
| Working capital | $31.96M | $143.52M | -$42.81M | $755.10M | — | -77.7% |
| Net tangible assets | -$263.88M | -$304.19M | -$349.98M | $652.38M | — | +13.3% |
| Shares issued | 163.06M | 160.21M | 156.35M | 154.03M | — | +1.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $24.02M | $880.00K | -$1.03B | $175.06M | — | +2,629.2% |
| Depreciation & amortisation | $1.88M | $2.01M | $1.57M | $1.42M | — | -6.5% |
| Stock-based compensation | $17.25M | $29.85M | $32.01M | $27.05M | — | -42.2% |
| Change in working capital | $41.34M | $739.00K | $11.28M | $2.82M | — | +5,493.8% |
| Operating cash flow | $127.04M | $103.55M | $183.43M | $273.76M | — | +22.7% |
| Capital expenditure | -$34.00K | -$142.00K | -$273.00K | -$136.00K | — | +76.1% |
| Investing cash flow | -$34.00K | -$142.00K | -$1.03B | -$136.00K | — | +76.1% |
| Share buybacks | — | $0 | $0 | -$126.39M | -$24.13M | — |
| Financing cash flow | $216.00K | -$106.97M | $277.16M | -$237.55M | — | +100.2% |
| Free cash flow | $127.01M | $103.41M | $183.15M | $273.63M | — | +22.8% |
| End cash position | $215.46M | $88.56M | $92.15M | $657.94M | — | +143.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $113.04M | $106.51M | $47.71M | $122.06M | $85.24M | +6.1% |
| Operating revenue | $113.04M | $106.51M | $47.71M | $122.06M | $85.24M | +6.1% |
| Research & development | $22.42M | $21.94M | $21.86M | $22.47M | $23.37M | +2.2% |
| Selling, general & admin | $11.31M | $12.03M | $19.29M | $21.91M | $16.80M | -6.0% |
| Total operating expense | $33.73M | $33.97M | $41.16M | $44.38M | $40.17M | -0.7% |
| Operating income | $79.31M | $72.53M | $6.55M | $77.68M | $45.07M | +9.3% |
| Net interest income | -$5.62M | -$7.44M | -$6.43M | -$7.50M | -$7.54M | +24.5% |
| Pre-tax income | $73.73M | $65.17M | $455.00K | $68.02M | $37.82M | +13.1% |
| Tax provision | $22.44M | $24.40M | $2.73M | $27.94M | $14.22M | -8.0% |
| Net income | $51.29M | $40.77M | -$2.28M | $40.08M | $23.60M | +25.8% |
| Net income to common | $51.29M | $40.77M | -$2.28M | $40.08M | $23.60M | +25.8% |
| Basic EPS | 0.31 | 0.25 | -0.01 | 0.25 | 0.15 | +24.0% |
| Diluted EPS | 0.31 | 0.24 | -0.01 | 0.23 | 0.14 | +29.2% |
| EBIT | $80.93M | $74.14M | $8.34M | $76.45M | $46.18M | +9.2% |
| EBITDA | $81.39M | $74.58M | $8.80M | $76.93M | $46.65M | +9.1% |
| Basic shares | 164.41M | 163.09M | 162.44M | 162.22M | 161.72M | +0.8% |
| Diluted shares | 167.18M | 169.89M | 162.44M | 177.76M | 176.84M | -1.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $79.13M | $220.47M | $215.46M | $140.41M | $92.85M | -64.1% |
| Cash & short-term investments | $79.13M | $220.47M | $215.46M | $140.41M | $92.85M | -64.1% |
| Accounts receivable | $112.73M | $105.84M | $46.74M | $120.37M | $86.17M | +6.5% |
| Total current assets | $199.20M | $332.29M | $274.18M | $273.84M | $191.75M | -40.1% |
| Property, plant & equipment | $11.36M | $12.06M | $12.75M | $13.44M | $14.13M | -5.9% |
| Goodwill & intangibles | $1.63M | $1.84M | $2.04M | $2.25M | $2.45M | -11.2% |
| Total assets | $285.13M | $434.57M | $396.90M | $396.06M | $342.95M | -34.4% |
| Total current liabilities | $32.85M | $236.31M | $242.22M | $242.50M | $232.53M | -86.1% |
| Current debt | — | $199.85M | $199.68M | $199.51M | $199.33M | — |
| Long-term debt | $385.00M | $385.00M | $385.00M | $385.00M | $385.00M | 0.0% |
| Total debt | $396.87M | $597.36M | $597.80M | $598.24M | $598.67M | -33.6% |
| Total liabilities | $446.97M | $651.71M | $658.74M | $660.22M | $651.11M | -31.4% |
| Retained earnings | -$1.58B | -$1.63B | -$1.67B | -$1.67B | -$1.71B | +3.1% |
| Shareholder equity | -$161.84M | -$217.14M | -$261.83M | -$264.16M | -$308.16M | +25.5% |
| Working capital | $166.35M | $95.98M | $31.96M | $31.34M | -$40.77M | +73.3% |
| Net tangible assets | -$163.48M | -$218.98M | -$263.88M | -$266.40M | -$310.62M | +25.3% |
| Shares issued | 165.24M | 164.61M | 163.06M | 162.68M | 162.43M | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $51.29M | $40.77M | -$2.28M | $40.08M | $23.60M | — | +25.8% |
| Depreciation & amortisation | $457.00K | $443.00K | $460.00K | $475.00K | $467.00K | — | +3.2% |
| Stock-based compensation | $3.24M | $3.65M | $3.82M | $3.61M | $4.52M | — | -11.4% |
| Change in working capital | -$12.72M | -$59.81M | $75.15M | -$25.21M | -$58.68M | — | +78.7% |
| Operating cash flow | $58.28M | $5.12M | $74.58M | $47.58M | -$15.07M | — | +1,038.0% |
| Capital expenditure | — | — | — | -$2.00K | -$2.00K | -$31.00K | — |
| Investing cash flow | $0 | $0 | $1.00K | -$2.00K | -$2.00K | — | — |
| Financing cash flow | -$199.70M | $0 | $122.00K | $0 | $88.00K | — | — |
| Free cash flow | $58.28M | $5.12M | $74.58M | $47.58M | -$15.07M | — | +1,038.0% |
| End cash position | $79.13M | $220.47M | $215.46M | $140.41M | $92.85M | — | -64.1% |
Options analytics
Put / call volume
0.10
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.50
-31.1% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
-50.0%
Calls bid over puts
Call volume
31
Contracts, this expiry
Put volume
3
Contracts, this expiry
Heaviest call OI
2.50
0 contracts
Heaviest put OI
5.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.28 | 0.31 | +12.7% |
| Mar 2026 | 0.24 | 0.24 | 0.0% |
| Dec 2025 | 0.01 | -0.01 | -200.0% |
| Sep 2025 | 0.12 | 0.24 | +108.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.31 | 2 | $121.57M | -0.4% |
| Next quarter | 0.34 | 2 | $128.25M | +168.8% |
| Current year | 1.21 | 2 | $471.43M | +59.2% |
| Next year | 1.50 | 3 | $494.05M | +4.8% |
Analyst targets & ownership
Mean target$6.10
High target$10.00
Low target$3.70
Implied upside68.98%
Analyst count4
ConsensusNONE
Strong buy / Buy1 / 1
Hold2
Sell / Strong sell0 / 0
Held by insiders3.24%
Held by institutions98.88%
Institutions holding290
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
3.95
-8.65% from price
SMA 20
4.08
-11.00% from price
SMA 50
4.15
-12.61% from price
SMA 100
3.99
-9.54% from price
SMA 200
4.00
-9.26% from price
EMA 12
3.93
-8.04% from price
EMA 26
4.05
-10.93% from price
EMA 50
4.09
-11.68% from price
RSI (14)
33.7
Neutral
MACD (12,26,9)
-0.13
Hist -0.07
ATR (14)
0.20
5.43% of price
Realised vol 30D
44.8%
Annualised
Bollinger upper
4.57
20, 2σ
Bollinger lower
3.59
20, 2σ
50 / 200 cross
Golden
4.15 vs 4.00
Trend bias
Below 200
-9.26%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.85
More volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
44.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-43.6%
Peak to trough
Max drawdown 5Y
-96.3%
Peak to trough
ATR 14
0.20
5.43% of price
Beta (reported)
0.22
5Y monthly, from filing
Short interest
Shares short
18.73M
Prior 18.07M
Change vs prior
+3.7%
Shorts adding
% of float
12.38%
Elevated
% of shares out
11.33%
Against total outstanding
Days to cover
12.8
Crowded exit
Float
136.76M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 26, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Jan 5, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Jan 5, 26 | Citizens | UPGRADE | Market Perform | Market Outperform |
| Nov 11, 25 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Apr 15, 25 | Wells Fargo | DOWNGRADE | Overweight | Equal-Weight |
| Apr 15, 25 | Jefferies | DOWNGRADE | Buy | Hold |
| Apr 14, 25 | Leerink Partners | MAINTAINED | Market Perform | Market Perform |
| Jan 30, 25 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
| Jan 22, 25 | Craig-Hallum | MAINTAINED | Buy | Buy |
| Sep 9, 24 | Leerink Partners | INITIATED | — | Market Perform |
| Aug 9, 24 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Aug 9, 24 | Craig-Hallum | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1194:1000
Split dateApr 2, 2019
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-06-18
Corporate Changes & Voting Matters
8-K · 2026-06-15
Corporate Changes & Voting Matters
8-K/A · 2026-05-21
Corporate Changes & Voting Matters
8-K · 2026-05-13
Corporate Changes & Voting Matters
8-K · 2026-05-07
Proxy Statements
DEFA14A · 2026-04-28
Corporate Changes & Voting Matters
8-K · 2026-03-11
Headlines
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
Zacks · 7d ago
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
Zacks · 23d ago
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
Business Wire · 33d ago
Ironwood (IRWD) Q2 2026 Earnings Call Transcript
Motley Fool · 54d ago
Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised
Zacks · 61d ago
Ironwood Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby · 61d ago
Ironwood Pharmaceuticals (IRWD) Is Up 14.2% After Raising 2026 Revenue Guidance – Has The Bull Case Changed?
Simply Wall St. · 61d ago
Ironwood Pharmaceuticals Inc (IRWD) (Q2 2026) Earnings Call Highlights: Strong LINZESS Growth ...
GuruFocus.com · 61d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.